Efficacy and Predictors of Discontinuation of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion Therapy in a Parkinson’s Disease Cohort (P3-17.007)
Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available
10.1212/wnl.0000000000213227